Subtype selective antagonism of substantia nigra pars compacta Group I metabotropic glutamate receptors protects the nigrostriatal system against 6-hydroxydopamine toxicity in vivo
- PMID: 17714448
- DOI: 10.1111/j.1471-4159.2007.04860.x
Subtype selective antagonism of substantia nigra pars compacta Group I metabotropic glutamate receptors protects the nigrostriatal system against 6-hydroxydopamine toxicity in vivo
Abstract
Evidence suggests that increased glutamatergic input to the substantia nigra pars compacta as a result of hyperactivity of subthalalmic nucleus output pathways may contribute to the progressive degeneration of nigral dopaminergic neurones in Parkinson's disease (PD), a debilitating neurodegenerative disorder which affects approximately 1% of people aged over 65. Substantial electrophysiological evidence suggests that the excitation of nigral dopaminergic neurones is regulated by the activation of Group I metabotropic glutamate receptors (mGluR), comprising mGluR1 and mGluR5 subtypes. As activation of these receptors by endogenous glutamate may promote multiple cascades leading to excitotoxic neuronal death, it may be hypothesised that functional antagonism of Group I mGluR should be neuroprotective and could form the basis of a novel neuroprotective treatment for PD. To investigate this hypothesis, the neuroprotective potential of the selective competitive mGlu1 antagonist (+)-2-methyl-4-carboxyphenylglycine ((S)-(+)-alpha-amino-4-carboxy-2-methlybenzeneacetic acid; LY367385) and the selective allosteric mGlu5 antagonist 2-methyl-6-(phenylethynyl)-pyridine (MPEP) was tested in a rodent 6-hydroxydopamine (6-OHDA) model of PD in vivo. Both acute and subchronic intranigral administration of either LY367385 or MPEP resulted in significant neuroprotection of nigral tyrosine hydroxylase immunoreactive cell bodies, which correlated closely with prevention of striatal monoamine depletion following 6-OHDA lesioning. This neuroprotective action of LY367385 and MPEP displayed a clear concentration-dependent effect, suggesting a receptor-mediated mechanism of action. LY367385 produced robust neuroprotection at all concentrations tested (40, 200 and 1000 nmol in 4 microL), whilst MPEP displayed a bell-shaped neuroprotective profile with significant neuroprotection at low concentrations (2 and 10 nmol in 4 microL) but not at higher concentrations (50 nmol). Importantly, subchronic intranigral administration of MPEP and LY367385 appeared to slow the degeneration of remaining nigral dopaminergic neurones and prevented further striatal dopamine depletion in animals with established 6-OHDA induced nigrostriatal lesions, suggesting that these compounds may significantly influence disease progression in this model.
Similar articles
-
Prolonged blockade of NMDA or mGluR5 glutamate receptors reduces nigrostriatal degeneration while inducing selective metabolic changes in the basal ganglia circuitry in a rodent model of Parkinson's disease.Neurobiol Dis. 2006 Apr;22(1):1-9. doi: 10.1016/j.nbd.2005.09.010. Epub 2005 Nov 11. Neurobiol Dis. 2006. PMID: 16289868
-
Effects of early and delayed treatment with an mGluR5 antagonist on motor impairment, nigrostriatal damage and neuroinflammation in a rodent model of Parkinson's disease.Brain Res Bull. 2010 Apr 29;82(1-2):29-38. doi: 10.1016/j.brainresbull.2010.01.011. Epub 2010 Jan 25. Brain Res Bull. 2010. PMID: 20100549
-
Chronic, systemic treatment with a metabotropic glutamate receptor 5 antagonist in 6-hydroxydopamine partially lesioned rats reverses abnormal firing of dopaminergic neurons.Brain Res. 2009 Aug 25;1286:192-200. doi: 10.1016/j.brainres.2009.06.040. Epub 2009 Jun 21. Brain Res. 2009. PMID: 19545547
-
The role of striatal metabotropic glutamate receptors in degeneration of dopamine neurons: review article.Amino Acids. 2002;23(1-3):199-205. doi: 10.1007/s00726-001-0129-z. Amino Acids. 2002. PMID: 12373538 Review.
-
Glutamate and Parkinson's disease.Mol Neurobiol. 1996 Feb;12(1):73-94. doi: 10.1007/BF02740748. Mol Neurobiol. 1996. PMID: 8732541 Review.
Cited by
-
Metabotropic glutamate receptor 1 mediates the electrophysiological and toxic actions of the cycad derivative beta-N-Methylamino-L-alanine on substantia nigra pars compacta DAergic neurons.J Neurosci. 2010 Apr 14;30(15):5176-88. doi: 10.1523/JNEUROSCI.5351-09.2010. J Neurosci. 2010. PMID: 20392940 Free PMC article.
-
EAAT2 Activation Regulates Glutamate Excitotoxicity and Reduces Impulsivity in a Rodent Model of Parkinson's Disease.Mol Neurobiol. 2025 May;62(5):5787-5803. doi: 10.1007/s12035-024-04644-0. Epub 2024 Dec 4. Mol Neurobiol. 2025. PMID: 39630405 Free PMC article.
-
Promising biomarkers and therapeutic targets for the management of Parkinson's disease: recent advancements and contemporary research.Metab Brain Dis. 2023 Mar;38(3):873-919. doi: 10.1007/s11011-023-01180-z. Epub 2023 Feb 20. Metab Brain Dis. 2023. PMID: 36807081 Review.
-
Clinically available iron chelators induce neuroprotection in the 6-OHDA model of Parkinson's disease after peripheral administration.J Neural Transm (Vienna). 2011 Feb;118(2):223-31. doi: 10.1007/s00702-010-0531-3. Epub 2010 Dec 17. J Neural Transm (Vienna). 2011. PMID: 21165659
-
In Silico Studies Targeting G-protein Coupled Receptors for Drug Research Against Parkinson's Disease.Curr Neuropharmacol. 2018;16(6):786-848. doi: 10.2174/1570159X16666180308161642. Curr Neuropharmacol. 2018. PMID: 29521236 Free PMC article.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Other Literature Sources
Research Materials
Miscellaneous